179 results
6-K
EX-99.1
GLPG
Galapagos NV
3 May 24
Galapagos reports first quarter 2024 financial results
9:30am
or diseases, may not support registration or further development of our product candidates due to safety or efficacy concerns or other reasons), risks
6-K
EX-99.1
GLPG
Galapagos NV
8 Apr 24
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
9:27am
to assess the safety, efficacy and feasibility of point-of-care manufactured GLPG5101 and GLPG5201 in patients with relapsed/refractory NHL, and relapsed … /refractory CLL and RT, respectively. The primary objective of the Phase 1 part of the studies is to evaluate the safety and preliminary efficacy
6-K
EX-99.2
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
, our drug candidates mentioned in this report are investigational; their efficacy and safety have not been fully evaluated by any regulatory authority … our ongoing and planned clinical research programs may not support registration or further development of our product candidates due to safety
6-K
EX-99.1
GLPG
Galapagos NV
23 Feb 24
Galapagos announces full year 2023 results and outlook for 2024
6:41am
.
GLPG5301 (BCMA CAR-T) in relapsed/refractory multiple myeloma (rrMM)First patients dosed in the PAPILIO-1 Phase 1/2 study to evaluate the safety … of the Pharmaceutical Risk Assessment Committee (PRAC) to add safety measures for the JAK inhibitors class of medicines.
Based on topline results from
6-K
EX-99.1
gniuoke
16 Feb 24
Galapagos presents at EBMT-EHA annual meeting 2024
6:00am
6-K
EX-99.1
j0kt3u
6 Feb 24
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
6:00am
6-K
EX-99.1
5a659pe
4 Jan 24
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
4:05pm
6-K
EX-99.1
2bcm2wbsi e08pwcr
21 Dec 23
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
4:03pm
6-K
EX-99.1
965h7phh7zh9e0
12 Dec 23
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
7:02am
6-K
EX-99.1
2a9r3pur sv
12 Dec 23
Current report (foreign)
6:00am
6-K
EX-99.1
orp1759p7j6gvhr
3 Nov 23
Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023
8:26am
6-K
EX-99.1
e49n9xdc7mvdgtaec9lg
2 Nov 23
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
7:15am
6-K
EX-99.1
fet3croihjxm
30 Aug 23
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
6:31am
6-K
EX-99.1
llr1rd
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.2
0tc0zs 4u0o2bp5pw
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.1
35u0kgz5sseyj8tc
12 Jun 23
Current report (foreign)
7:32am
6-K
EX-99.1
0ipumv633 8n
25 May 23
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis
5:49pm
6-K
EX-99.1
l80cnc
23 May 23
Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023
7:30am
6-K
EX-99.1
4dv9x
5 May 23
Galapagos announces first quarter 2023 financial results
4:05pm